Novartis AG (NYSE:NVS) has earned an average recommendation of “Hold” from the nineteen analysts that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $81.59.

NVS has been the topic of a number of recent analyst reports. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis AG in a report on Tuesday, September 5th. BidaskClub upgraded shares of Novartis AG from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Cowen and Company reiterated a “hold” rating on shares of Novartis AG in a research note on Tuesday, July 18th. Zacks Investment Research lowered shares of Novartis AG from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Finally, Barclays PLC upgraded shares of Novartis AG from an “underweight” rating to an “equal weight” rating in a research note on Thursday, June 22nd.

A number of institutional investors have recently bought and sold shares of the business. Farr Miller & Washington LLC DC grew its position in Novartis AG by 0.3% in the second quarter. Farr Miller & Washington LLC DC now owns 2,959 shares of the company’s stock worth $247,000 after buying an additional 10 shares during the last quarter. FCG Advisors LLC grew its position in Novartis AG by 0.3% in the second quarter. FCG Advisors LLC now owns 4,271 shares of the company’s stock worth $357,000 after buying an additional 12 shares during the last quarter. Washington Trust Bank grew its position in Novartis AG by 0.3% in the second quarter. Washington Trust Bank now owns 4,384 shares of the company’s stock worth $366,000 after buying an additional 14 shares during the last quarter. North Star Investment Management Corp. grew its position in Novartis AG by 1.0% in the second quarter. North Star Investment Management Corp. now owns 1,542 shares of the company’s stock worth $129,000 after buying an additional 16 shares during the last quarter. Finally, Ledyard National Bank grew its position in Novartis AG by 0.9% in the second quarter. Ledyard National Bank now owns 3,428 shares of the company’s stock worth $286,000 after buying an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 10.92% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Novartis AG (NVS) Given Consensus Recommendation of “Hold” by Brokerages” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/10/12/novartis-ag-nvs-given-consensus-recommendation-of-hold-by-brokerages.html.

Novartis AG (NYSE NVS) traded down 0.46% during trading on Thursday, reaching $85.99. The company’s stock had a trading volume of 1,229,028 shares. The firm has a 50 day moving average of $85.07 and a 200 day moving average of $81.69. Novartis AG has a 52 week low of $66.93 and a 52 week high of $86.90. The stock has a market capitalization of $201.47 billion, a price-to-earnings ratio of 31.39 and a beta of 0.73.

Novartis AG (NYSE:NVS) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.06. The company had revenue of $12.24 billion for the quarter, compared to analysts’ expectations of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The business’s revenue for the quarter was down 1.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 earnings per share. Analysts expect that Novartis AG will post $4.75 EPS for the current year.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.